Dual components of optimal asthma therapy: Scientific and clinical rationale for the use of long-acting β-agonists with inhaled corticosteroids

Ronnann Naedele-Risha, Paul Dorinsky, Timothy Craig

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The authors describe the scientific rationale for using an inhaled corticosteroid with an inhaled long-acting β2-agonist. They discuss the clinical trials demonstrating that using an inhaled corticosteroid with an inhaled long-acting β2-agonist provides greater overall asthma control compared with increasing the dose of inhaled corticosteroid. In addition, they review the clinical trials comparing the addition of a leukotriene modifier to an inhaled corticosteroid versus using an inhaled corticosteroid with an inhaled long-acting β2-agonist. Discussion also includes descriptions of trials showing reduced exacerbations of asthma when using an inhaled corticosteroid with an inhaled long-acting β2-agonist. Finally, the authors provide evidence for the ability to detect deteriorating asthma when using an inhaled corticosteroid with an inhaled long-acting β2-agonist, and they provide a comparison of salmeterol and formoterol, two long-acting β2-agonists.

Original languageEnglish (US)
Pages (from-to)526-533
Number of pages8
JournalJournal of the American Osteopathic Association
Volume101
Issue number9
StatePublished - Oct 1 2001

Fingerprint

Adrenal Cortex Hormones
Asthma
Therapeutics
Clinical Trials
Leukotrienes

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine

Cite this

@article{066010e9af164d818f7d24b97c296410,
title = "Dual components of optimal asthma therapy: Scientific and clinical rationale for the use of long-acting β-agonists with inhaled corticosteroids",
abstract = "The authors describe the scientific rationale for using an inhaled corticosteroid with an inhaled long-acting β2-agonist. They discuss the clinical trials demonstrating that using an inhaled corticosteroid with an inhaled long-acting β2-agonist provides greater overall asthma control compared with increasing the dose of inhaled corticosteroid. In addition, they review the clinical trials comparing the addition of a leukotriene modifier to an inhaled corticosteroid versus using an inhaled corticosteroid with an inhaled long-acting β2-agonist. Discussion also includes descriptions of trials showing reduced exacerbations of asthma when using an inhaled corticosteroid with an inhaled long-acting β2-agonist. Finally, the authors provide evidence for the ability to detect deteriorating asthma when using an inhaled corticosteroid with an inhaled long-acting β2-agonist, and they provide a comparison of salmeterol and formoterol, two long-acting β2-agonists.",
author = "Ronnann Naedele-Risha and Paul Dorinsky and Timothy Craig",
year = "2001",
month = "10",
day = "1",
language = "English (US)",
volume = "101",
pages = "526--533",
journal = "The Journal of the American Osteopathic Association",
issn = "0098-6151",
publisher = "American Osteopathic Association",
number = "9",

}

Dual components of optimal asthma therapy : Scientific and clinical rationale for the use of long-acting β-agonists with inhaled corticosteroids. / Naedele-Risha, Ronnann; Dorinsky, Paul; Craig, Timothy.

In: Journal of the American Osteopathic Association, Vol. 101, No. 9, 01.10.2001, p. 526-533.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Dual components of optimal asthma therapy

T2 - Scientific and clinical rationale for the use of long-acting β-agonists with inhaled corticosteroids

AU - Naedele-Risha, Ronnann

AU - Dorinsky, Paul

AU - Craig, Timothy

PY - 2001/10/1

Y1 - 2001/10/1

N2 - The authors describe the scientific rationale for using an inhaled corticosteroid with an inhaled long-acting β2-agonist. They discuss the clinical trials demonstrating that using an inhaled corticosteroid with an inhaled long-acting β2-agonist provides greater overall asthma control compared with increasing the dose of inhaled corticosteroid. In addition, they review the clinical trials comparing the addition of a leukotriene modifier to an inhaled corticosteroid versus using an inhaled corticosteroid with an inhaled long-acting β2-agonist. Discussion also includes descriptions of trials showing reduced exacerbations of asthma when using an inhaled corticosteroid with an inhaled long-acting β2-agonist. Finally, the authors provide evidence for the ability to detect deteriorating asthma when using an inhaled corticosteroid with an inhaled long-acting β2-agonist, and they provide a comparison of salmeterol and formoterol, two long-acting β2-agonists.

AB - The authors describe the scientific rationale for using an inhaled corticosteroid with an inhaled long-acting β2-agonist. They discuss the clinical trials demonstrating that using an inhaled corticosteroid with an inhaled long-acting β2-agonist provides greater overall asthma control compared with increasing the dose of inhaled corticosteroid. In addition, they review the clinical trials comparing the addition of a leukotriene modifier to an inhaled corticosteroid versus using an inhaled corticosteroid with an inhaled long-acting β2-agonist. Discussion also includes descriptions of trials showing reduced exacerbations of asthma when using an inhaled corticosteroid with an inhaled long-acting β2-agonist. Finally, the authors provide evidence for the ability to detect deteriorating asthma when using an inhaled corticosteroid with an inhaled long-acting β2-agonist, and they provide a comparison of salmeterol and formoterol, two long-acting β2-agonists.

UR - http://www.scopus.com/inward/record.url?scp=0034830219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034830219&partnerID=8YFLogxK

M3 - Review article

C2 - 11575039

AN - SCOPUS:0034830219

VL - 101

SP - 526

EP - 533

JO - The Journal of the American Osteopathic Association

JF - The Journal of the American Osteopathic Association

SN - 0098-6151

IS - 9

ER -